Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | QPCT | Q16769 | 1/20 | 0.46 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL365933 | 0.82 | — | — | |
| Water SCHEMBL9578432 | 0.82 | MAPT (0.50) | HSD17B10CYP1A2MEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL28196424 | 0.80 | MAPT (0.48) | HSD17B10MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL9710096 | 0.78 | MAPT (0.46) | MEN1KMT2AMAPTALDH1A1PKM | |
| 1-Methylimidazole SCHEMBL9113348 | 0.73 | QPCT (0.65) | HSD17B10NFKB1QPCTQPCTLCYP3A4 | |
| 1-Methylimidazole SCHEMBL6522952 | 0.72 | CYP1A2 (0.42) | HSD17B10NFKB1QPCTQPCTLCYP3A4 | |
| 1-Methylimidazole SCHEMBL21819897 | 0.70 | — | — | |
| 1-Methylimidazole SCHEMBL27765984 | 0.70 | QPCT (0.75) | HSD17B10NFKB1QPCTQPCTLCYP3A4 | |
| 1-Methylimidazole SCHEMBL11219255 | 0.70 | NFKB1 (0.50) | HSD17B10NFKB1QPCTQPCTLCYP3A4 | |
| SCHEMBL5482125 | 0.70 | SMN1; SMN2 (0.48) | CYP3A4CYP2C9CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158432-A1 | COMPOSITIONS COMPRISING DICHLOROACETIC ACID, PROCESSES FOR PREPARING SAME AND USES THEREOF | SHANGHAI STA PHARMACEUTICAL R&D CO., LTD. (CN) | 2024-05-16 | — | — | US | disclosed |
| US-11873318-B2 | Compositions comprising dichloroacetic acid, processes for preparing same and uses thereof | CHANGZHOU SYNTHEALL PHARMACEUTICALS CO., LTD. (CN) | 2024-01-16 | — | — | US | disclosed |
| EP-4153605-A1 | COMPOSITIONS COMPRISING DICHLOROACETIC ACID, PROCESSES FOR PREPARING SAME AND USES THEREOF | Changzhou Syntheall Pharmaceuticals Co., Ltd. (CN) | 2023-03-29 | — | — | EP | disclosed |
| US-20230002438-A1 | COMPOSITIONS COMPRISING DICHLOROACETIC ACID, PROCESSES FOR PREPARING SAME AND USES THEREOF | SHANGHAI STA PHARMACEUTICAL R&D CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| WO-2021233406-A1 | COMPOSITIONS COMPRISING DICHLOROACETIC ACID, PROCESSES FOR PREPARING SAME AND USES THEREOF | CHANGZHOU SYNTHEALL PHARMACEUTICALS CO., LTD. (CN) | 2021-11-25 | — | — | WO | disclosed |
| US-7446193-B2 | Methods for detection of chloral hydrate in dichloroacetic acid | ISIS PHARMACEUTICALS, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-20070196847-A1 | METHODS FOR DETECTION OF CHLORAL HYDRATE IN DICHLOROACETIC ACID | ISIS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| EP-1496943-A4 | OLIGOMERIC COMPOUNDS HAVING MODIFIED PHOSPHATE GROUPS | ISIS PHARMACEUTICALS INC (US) | 2007-05-23 | — | — | EP | disclosed |
| US-7173123-B2 | Methods for detection of chloral hydrate in dichloroacetic acid | ISIS PHARMACEUTICALS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| EP-1356115-B1 | METHODS FOR DETECTION OF CHLORAL HYDRATE IN DICHLOROACETIC ACID | ISIS PHARMACEUTICALS INC (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-1356115-A4 | METHODS FOR DETECTION OF CHLORAL HYDRATE IN DICHLOROACETIC ACID | ISIS PHARMACEUTICALS INC (US) | 2004-06-23 | — | — | EP | disclosed |
| CN-1489633-A | Method for detecting chloral hydrate in dichloroacetic acid | ISISҩ�﹫˾ | 2004-04-14 | — | — | CN | disclosed |
| US-6645716-B2 | Detecting nuclear magnetic resonance spectrum of chloral hydrate in sample; obtain sample of dichloroacetic acid, monitor resonance spectrum for presence of chloral hydrate | ISIS PHARMACEUTICALS, INC. | 2003-11-11 | — | — | US | disclosed |
| EP-1356115-A1 | METHODS FOR DETECTION OF CHLORAL HYDRATE IN DICHLOROACETIC ACID | ISIS PHARMACEUTICALS, INC. (US) | 2003-10-29 | — | — | EP | disclosed |
| WO-2003087115-A2 | OLIGOMERIC COMPOUNDS HAVING MODIFIED PHOSPHATE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030190626-A1 | Phosphorothioate monoester modified oligomers | ISIS PHARMACEUTICALS, INC. | 2003-10-09 | — | — | US | disclosed |
| EP-1311526-A1 | PROCESSES FOR THE PREPARATION OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020119483-A1 | Methods for detection of chloral hydrate in dichloroacetic acid | IONIS PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002061138-A1 | METHODS FOR DETECTION OF CHLORAL HYDRATE IN DICHLOROACETIC ACID | ISIS PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| WO-2002014340-A1 | PROCESSES FOR THE PREPARATION OF OLIGONUCLEOTIDES_______________ | ISIS PHARMACEUTICALS, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030190626-A1 | Phosphorothioate monoester modified oligomers | DCLRE1B, SNRPE, POLRMT | HSD17B10 3024/4885NFKB1 2082/4885QPCT 3146/4885 |
| US-20230002438-A1 | COMPOSITIONS COMPRISING DICHLOROACETIC ACID, PROCESSES FOR PREPARING SAME AND USES THEREOF | AGXT, DDC, GRHPR | HSD17B10 433/4885NFKB1 4147/4885QPCT 1670/4885 |
| US-20240158432-A1 | COMPOSITIONS COMPRISING DICHLOROACETIC ACID, PROCESSES FOR PREPARING SAME AND USES THEREOF | AGXT, DDC, DERA | HSD17B10 1655/4885NFKB1 4302/4885QPCT 1254/4885 |
| US-11873318-B2 | Compositions comprising dichloroacetic acid, processes for preparing same and uses thereof | AGXT, DDC, GRHPR | HSD17B10 433/4885NFKB1 4147/4885QPCT 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.